These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 1810268)

  • 1. Quality aspects of fibrinolytic agents based on biochemical characterization.
    Werner RG; Bassarab S; Hoffmann H; Schlüter M
    Arzneimittelforschung; 1991 Nov; 41(11):1196-200. PubMed ID: 1810268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombolytic treatment in acute myocardial infarction.
    Verstraete M
    Circulation; 1990 Sep; 82(3 Suppl):II96-109. PubMed ID: 2118432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronary thrombolysis with clot-selective plasminogen activators.
    Collen D; Bounameaux H
    Herz; 1986 Feb; 11(1):9-15. PubMed ID: 3082731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New thrombolytic agents].
    Nguyen G; Samama M
    Ann Biol Clin (Paris); 1987; 45(2):212-8. PubMed ID: 3113300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acylated plasminogen-streptokinase activator complex: a new approach to thrombolytic therapy.
    Crabbe SJ; Grimm AM; Hopkins LE
    Pharmacotherapy; 1990; 10(2):115-26. PubMed ID: 2140889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Thrombolytic drugs in acute myocardial infarct].
    Ambrosioni E; Degli Esposti D
    Cardiologia; 1991 Dec; 36(12 Suppl 1):395-402. PubMed ID: 1841796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative tolerability profiles of thrombolytic agents. A review.
    Woo KS; White HD
    Drug Saf; 1993 Jan; 8(1):19-29. PubMed ID: 8471185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro comparison of fibrinolytic activity of plasminogen activators using a thrombelastographic method: in vivo evaluation of the B-chain-streptokinase complex in the dog model using pre-titered doses.
    Summaria L; Sandesara J; Yang G; Vagher JP; Caprini JA
    Thromb Haemost; 1986 Aug; 56(1):71-9. PubMed ID: 2946093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective fibrinolytic activity of recombinant non-glycosylated human pro-urokinase (single-chain urokinase-type plasminogen activator) from bacteria.
    Hanbücken FW; Schneider J; Günzler WA; Friderichs E; Giertz H; Flohé L
    Arzneimittelforschung; 1987 Aug; 37(8):993-7. PubMed ID: 3118890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Present-day thrombolytic therapy: therapeutic agents--pharmacokinetics and pharmacodynamics.
    Bell WR
    Rev Cardiovasc Med; 2002; 3 Suppl 2():S34-44. PubMed ID: 12556741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The susceptibility of plasma to activation of fibrinolysis.
    Stief TW
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):123-5. PubMed ID: 8457639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of the activity and content of different streptokinase preparations.
    Hermentin P; Cuesta-Linker T; Weisse J; Schmidt KH; Knorst M; Scheld M; Thimme M
    Eur Heart J; 2005 May; 26(9):933-40. PubMed ID: 15637085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of the pharmacological profile of thrombolytic agents in clinical practice.
    Alpert JS
    Am J Cardiol; 1991 Dec; 68(16):3E-7E. PubMed ID: 1746449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thrombolytic agents: efficacy in relation to evolution time and dose].
    García Frade LJ; Torrado MC; Loren M; Navarro JL
    Rev Clin Esp; 1989 Feb; 184(2):75-9. PubMed ID: 2502822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombolytic treatment of acute pulmonary embolism.
    Charbonnier B; Meyer G; Stern M; Sors H; Brochier ML
    Herz; 1989 Jun; 14(3):157-71. PubMed ID: 2500388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Binding of an acylated plasminogen activator-streptokinase complex with fibrin and the fibrinolytic response in vitro].
    Aĭsina RB; Zhitkova IuV; Varfolomeev SD
    Vopr Med Khim; 1994; 40(3):31-5. PubMed ID: 8079435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells.
    Collen D; Stassen JM; Marafino BJ; Builder S; De Cock F; Ogez J; Tajiri D; Pennica D; Bennett WF; Salwa J
    J Pharmacol Exp Ther; 1984 Oct; 231(1):146-52. PubMed ID: 6541693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
    Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.